What is the latest news on KZIA?

In the last 30 days Quantisnow tracked 7 wire items for KZIA: 4 press releases and news items and 3 analyst ratings. The most recent was published on November 12, 2026.

What is KZIA revenue?

Kazia Therapeutics Limited (KZIA) reported A$42.0K of revenue for fiscal 2025 (ended Jun 30, 2025). That is down 98.2% from the year before.

No. Kazia Therapeutics Limited reported a net loss of A$20.70M for fiscal 2025 (ended Jun 30, 2025).

How much cash and debt does KZIA have?

Kazia Therapeutics Limited reported A$4.34M in cash and cash equivalents on its most recent balance sheet in SEC filings.

Where does KZIA stock trade?

Kazia Therapeutics Limited (KZIA) is listed on NASDAQ.

What sector and industry is KZIA in?

Kazia Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

What are analysts saying about KZIA?

Kazia Therapeutics Limited has had 8 recent analyst actions on file. The most recent action was from Needham: Buy with a $27.00 price target on 2026-10-30.

What companies are similar to KZIA?

Notable peers in the same industry include NVCR (NovoCure Limited), DNLI (Denali Therapeutics Inc.), CLRB (Cellectar Biosciences Inc.), PCVX (Vaxcyte Inc.). Compare KZIA side-by-side with any of them on Quantisnow.

How can I track KZIA on Quantisnow?

Quantisnow aggregates Kazia Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KZIA to receive live email and push alerts on every new disclosure.

KZIA

NASDAQ

Kazia Therapeutics Limited

SectorHealth Care IndustryBiotechnology: Pharmaceutical Preparations

Follow + get alerts

Website

Kazia Therapeutics Limited (KZIA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for KZIA, including 4 press releases and news items and 3 analyst ratings. The most recent was published Nov 12, 2026.

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

KZIA rankings

Financial highlights

Full financials

Revenue, FY2025: A$42.0K
Revenue growth: -98.2%
Net income, FY2025: -A$20.70M
Net margin: -49290.5%
Cash: A$4.34M

For fiscal 2025 (ended Jun 30, 2025), from SEC filings. Not investment advice.

News · 26 weeks78+17%

2026-05-172026-11-08

Mix4590d

SEC Filings30(67%)
Other9(20%)
Offering3(7%)
Analyst3(7%)

Activity · 52 weeks14848 active days

Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

KZIA FAQ

10 questions

What does Kazia Therapeutics Limited do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
What is the latest news on KZIA?
In the last 30 days Quantisnow tracked 7 wire items for KZIA: 4 press releases and news items and 3 analyst ratings. The most recent was published on November 12, 2026.
What is KZIA revenue?
Kazia Therapeutics Limited (KZIA) reported A$42.0K of revenue for fiscal 2025 (ended Jun 30, 2025). That is down 98.2% from the year before.
Is KZIA profitable?
No. Kazia Therapeutics Limited reported a net loss of A$20.70M for fiscal 2025 (ended Jun 30, 2025).
How much cash and debt does KZIA have?
Kazia Therapeutics Limited reported A$4.34M in cash and cash equivalents on its most recent balance sheet in SEC filings.
Where does KZIA stock trade?
Kazia Therapeutics Limited (KZIA) is listed on NASDAQ.
What sector and industry is KZIA in?
Kazia Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
What are analysts saying about KZIA?
Kazia Therapeutics Limited has had 8 recent analyst actions on file. The most recent action was from Needham: Buy with a $27.00 price target on 2026-10-30.
What companies are similar to KZIA?
Notable peers in the same industry include NVCR (NovoCure Limited), DNLI (Denali Therapeutics Inc.), CLRB (Cellectar Biosciences Inc.), PCVX (Vaxcyte Inc.). Compare KZIA side-by-side with any of them on Quantisnow.
How can I track KZIA on Quantisnow?
Quantisnow aggregates Kazia Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KZIA to receive live email and push alerts on every new disclosure.